Increase decrease in general and administrative expenes.

No definition available.

Name:	IMNN_IncreaseDecreaseInGeneralAndAdministrativeExpenes
Namespace Prefix:	IMNN_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Increase decrease in general and administrative expenses percentage.

+ References

No definition available.

+ Details

Name:	IMNN_IncreaseDecreaseInGeneralAndAdministrativeExpensesPercentage
Namespace Prefix:	IMNN_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Increase decrease in loss from operations.

+ References

No definition available.

+ Details

Name:	IMNN_IncreaseDecreaseInLossFromOperations
Namespace Prefix:	IMNN_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Increase decrease in loss from operations percentage.

+ References

No definition available.

+ Details

Name:	IMNN_IncreaseDecreaseInLossFromOperationsPercentage
Namespace Prefix:	IMNN_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Increase decrease in operating cost and expenses.

+ References

No definition available.

+ Details

Name:	IMNN_IncreaseDecreaseInOperatingCostAndExpenses
Namespace Prefix:	IMNN_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Increase decrease in operating costs and expenses percentage.

+ References

No definition available.

+ Details

Name:	IMNN_IncreaseDecreaseInOperatingCostsAndExpensesPercentage
Namespace Prefix:	IMNN_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Increase decrease in operating expenses.

+ References

No definition available.

+ Details

Name:	IMNN_IncreaseDecreaseInOperatingExpenses
Namespace Prefix:	IMNN_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Increase decrease in operating expenses percentage.

+ References

No definition available.

+ Details

Name:	IMNN_IncreaseDecreaseInOperatingExpensesPercentage
Namespace Prefix:	IMNN_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Increase decrease in research and development expenses percentage.

+ References

No definition available.

+ Details

Name:	IMNN_IncreaseDecreaseInResearchAndDevelopmentExpensesPercentage
Namespace Prefix:	IMNN_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

+ Details

Name:	us-gaap_GeneralAndAdministrativeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingCostsAndExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

+ Details

Name:	us-gaap_OperatingExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

+ Details

Name:	us-gaap_OperatingIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=IMNN_ClinicalResearchMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsegmentsAxis=IMNN_OvationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsegmentsAxis=IMNN_PlaccineVaccineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsegmentsAxis=IMNN_OtherClinicalAndRegulatoryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=IMNN_NonClinicalRAndDAndCMCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsegmentsAxis=IMNN_ManufacturingCMCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Schedule of Significant Expense Categories and Consolidated Net Loss (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Segment Reporting Information [Line Items]
Research and development expenses	$ 1,226,954	$ 2,819,645	$ 3,392,046	$ 6,113,506
General and administrative expenses	1,540,910	2,193,706	3,521,117	3,911,291
Total operating expenses	2,767,864	5,013,351	6,913,163	10,024,797
Loss from operations	$ (2,767,864)	$ (5,013,351)	(6,913,163)	(10,024,797)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Change Increase (Decrease), Research and development expenses			(2,722,000)
Research and development expenses			$ 3,392,000	6,114,000
Change Increase (Decrease), Research and development expenses, percentage			(44.50%)
General and administrative expenses			$ 3,521,000	3,911,000
Change Increase (Decrease), General and administrative expenses			$ (390,000)
Change Increase (Decrease), General and administrative expenses, percentage			(10.00%)
Total operating expenses			$ 6,913,000	10,025,000
Change Increase (Decrease), Operating expenses			$ (3,112,000)
Change Increase (Decrease), Operating expenses, percentage			(31.00%)
Loss from operations			$ (6,913,000)	(10,025,000)
Change Increase (Decrease), Loss from operations			$ (3,112,000)
Change Increase (Decrease), Loss from operations, percentage			(31.00%)
Operating Segments [Member] \| Clinical Research [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 1,366,000	2,710,000
Change Increase (Decrease), Research and development expenses			$ (1,344,000)
Change Increase (Decrease), Subtotal, percentage			(49.60%)
Operating Segments [Member] \| Clinical Research [Member] \| Ovation [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 382,000	721,000
Change Increase (Decrease), Research and development expenses			$ (339,000)
Change Increase (Decrease), Subtotal, percentage			(47.00%)
Operating Segments [Member] \| Clinical Research [Member] \| Placcine Vaccine [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 33,000	889,000
Change Increase (Decrease), Research and development expenses			$ (856,000)
Change Increase (Decrease), Subtotal, percentage			(96.30%)
Operating Segments [Member] \| Clinical Research [Member] \| Other Clinical And Regulatory [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 951,000	1,100,000
Change Increase (Decrease), Research and development expenses			$ (149,000)
Change Increase (Decrease), Subtotal, percentage			(13.50%)
Operating Segments [Member] \| Non-Clinical R&D and CMC [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 2,026,000	3,404,000
Change Increase (Decrease), Research and development expenses			$ (1,378,000)
Change Increase (Decrease), Subtotal, percentage			(40.50%)
Operating Segments [Member] \| Non-Clinical R&D and CMC [Member] \| Ovation [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 1,485,000	652,000
Change Increase (Decrease), Research and development expenses			$ 833,000
Change Increase (Decrease), Subtotal, percentage			127.80%
Operating Segments [Member] \| Non-Clinical R&D and CMC [Member] \| Placcine Vaccine [Member]
Segment Reporting Information [Line Items]
Subtotal				1,956,000
Change Increase (Decrease), Research and development expenses			$ (1,956,000)
Change Increase (Decrease), Subtotal, percentage
Operating Segments [Member] \| Non-Clinical R&D and CMC [Member] \| Manufacturing (CMC) [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 541,000	$ 796,000
Change Increase (Decrease), Research and development expenses			$ (255,000)
Change Increase (Decrease), Subtotal, percentage			(32.00%)